COMPARE
Three Peptides, One Signaling Neighborhood, Three Different Stories
One is FDA-approved. One is investigational and closely supervised. One is unapproved and carries the most serious documented risk. Here is how the mechanism and the evidence actually compare.
The short version
All three peptides on this site touch the reproductive and sexual-arousal system, but they are not interchangeable and should not be read as three flavors of the same thing. PT-141 (bremelanotide) is a receptor-selective melanocortin agonist with an FDA approval for HSDD in premenopausal women behind it. Kisspeptin works upstream of the whole cascade, on the hypothalamic switch that starts reproductive hormone signaling, and remains investigational. Melanotan II shares PT-141's chemistry but binds every melanocortin receptor rather than two, and carries the most serious safety record documented here — it has never been approved for any use.
The table below lines up mechanism, regulatory status, and what each was actually studied for, so the differences are visible at a glance rather than buried in three separate pages.
Side by side
| PT-141 (bremelanotide) | Kisspeptin | Melanotan II | |
|---|---|---|---|
| Receptor target | MC4R, MC3R (selective) | KISS1R on GnRH neurons | MC1R-MC5R (non-selective) |
| Regulatory status | FDA-approved (HSDD, premenopausal women) [5] | Not approved anywhere; investigational | Not approved anywhere; sold as research chemical |
| Deepest evidence | Two Phase 3 RCTs + 52-week extension, n=1,267 / 684 [3][4] | 29 completed trials; largest fertility RCT n=60 [9][10] | Small Phase 1 studies only, n=3-20 [16][17] |
| Primary studied effect | Sexual desire, HSDD | LH/FSH pulse restoration; oocyte maturation trigger | Skin pigmentation; appetite; erectile response |
| Most-reported adverse effect | Nausea (~40% long-term) [4] | Mild, short-lived; tachyphylaxis with repeat dosing [11] | Nausea, flushing; serious case reports of mole change and renal injury [15] |
| Serious documented harms | Transient blood-pressure rise; rare liver-enzyme changes [5] | None reported in controlled human studies to date | Melanoma, renal infarction, rhabdomyolysis, priapism, PRES |
Reading the differences
The single variable that explains the most about these three is receptor selectivity. PT-141 was deliberately engineered toward two central receptors and carried that selectivity through a full Phase 3 program to an FDA approval [3][5]. Melanotan II shares its parent chemistry but was never narrowed the same way, and that lack of selectivity is the direct mechanistic reason it produces skin pigmentation, appetite suppression, and sexual effects simultaneously — and why its case-report safety literature is the widest of the three [16].
Kisspeptin is a different kind of comparison altogether, because it does not act on the melanocortin receptors at all. It sits one step earlier in the biology, on the hypothalamic signal that starts the hormone cascade those two peptides' downstream effects depend on. Its clinical development has also been the most conservative: every study to date has run under direct medical supervision at a small number of academic centers, and unlike Melanotan II, it has essentially no consumer black-market presence to generate case reports from [9].
Evidence maturity is the second axis worth separating from mechanism. "Studied" does not mean the same thing across these three. PT-141's evidence includes two identical, large, placebo-controlled Phase 3 trials plus a year of open-label follow-up — the closest thing to a settled evidence base on this site [3][4]. Kisspeptin's evidence is real but early-phase: mechanistically consistent, replicated across a couple of dozen small trials, but without a completed pivotal trial for any single indication [9]. Melanotan II's evidence for its intended uses is the thinnest of the three — small, decades-old Phase 1 studies — while its evidence for harm is the most extensive, built almost entirely from case reports generated by unsupervised self-administration outside any research protocol [15][16].
Where to go next
For depth on any one compound, start with PT-141, kisspeptin, or Melanotan II. Every claim across all three pages traces back to the numbered source on the references list.